Travere Therapeutics (TVTX) reported $81.73 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 97.6$0.47 for the same period compares to -$1.76 a year ago.The reported revenue compares to the Zacks Consensus Estimate of$79.35 million, representing a surprise of +3.00%. The company delivered an EPS surprise of +14.55%, with the consensus EPS estimate being -$0.55.While investors scrutinize revenue and earnings changes year-over-year and how they compare ...